Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Shiseido Arbitration

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Aug 13, 2022 9:54am

137 Views

Post# 34893807

RE:RE:RE:Shiseido Arbitration

Are you speculating they might be working on a deal or have you heard somethng ? One thing we forget about is Replicel I assume has patents surrounding RCH-01. One way or another Shiseido has to honour those patents. The cannot just receive the initial transfer of technology as per the contract then just move on saying they no longer recognize the contract and continue to use RCH-01. I am sure this is one of the key issues in the arbitration.

<< Previous

Bullboard Posts

Next >>

AI companies to invest in